Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults.

Published in: British journal of clinical pharmacology (2022)

The results suggest that the DWP16001 could be added to metformin and gemigliptin combination therapy without dose adjustment.

Keyphrases